 2009 |
|
 December 25 |
Issuance of Notice of Termination of the License Agreement with Transcription Factor Therapeutics, LLC, on NF-κB Decoy |
| November 24 |
Agreement on SPA with the US FDA for Phase III Clinical Trial for CollategeneTM,
a Drug for Ischemic Disease Treatment |
| November 24 |
Product Patent on Dumbbell-Type (Ribbon-Type) E2F Decoy Oligonucleotide Granted in Japan
--- Covering a Circular Oligonucleotide Sequence --- |
| October 22 |
Patent on New Decoy Oligonucleotide Granted in Japan
—Covering NF-κB/ets chimera (double) decoy— |
| September 3 |
AnGes MG Project Adopted by NEDO as Next Generation Strategic Business Program
– Development of Drug-Eluting PTA Balloon Catheter – |
| August 31 |
Project of AnGes MG Subsidiary GenomIdea Adopted as Strategic Basic Technology Sophistication Supportive Program - R&D of New Method for Biopharmaceuticals Manufacturing Using Technology to Maintain Vacuum - |
| July 29 |
Medical-Use Patent on NF-κB Decoy Oligonucleotide Granted in Japan
- Covering Psoriasis - |
| July 14 |
AnGes Project Selected by R&D Project for Creation of Regional Innovation
-Development of Medical Products Based on Functional Peptides Derived from Plant
Regeneration Mechanism- |
| April 27 |
Joint R&D with Morishita Jintan Co., Ltd.-Development of New Products Based on Functional Peptides with Antimicrobial Activity- |
| April 15 |
Substance Patent on Dumbbell-Type (Ribbon-Type)
NF-κB Decoy Oligonucleotide Granted in Japan
-Covering a Circular Oligonucleotide Sequence- |
| March 26 |
AnGes Project Adopted to Receive NEDO Support
- Development of Novel Disinfectants with Antibacterial Peptides - |
| March 2 |
AnGes Reached a Broad Agreement with the FDA
on the Clinical Trial Designs for Their
Phase III Study with Collategene™ |
| February 16 |
Announcement about the progress of Allovectin-7® Phase 3 pivotal trial |
| February 6 |
AnGes MG continues the collaborations of plasmid HGF for Japan market with
Daiichi-Sankyo while the US/Europe marketing rights are returned |
| February 4 |
Efficacy of NF-κB decoy oligodeoxynucleotides for periodontal disease confirmed in an animal study
-An academic paper published in the scientific journal, Antioxidants & Redox Signaling- |
| February 2 |
GenomIdea, a Subsidiary of AnGes MG, Signs a Licensing Contract for GEN0101 |
 |
|
